3-3-2015

Unlocking the Mysteries of TDP-43

Keith A. Josephs  
*Mayo Clinic*

Peter T. Nelson  
*University of Kentucky, pnels2@uky.edu*

[Click here to let us know how access to this document benefits you.](https://uknowledge.uky.edu/sbcoa_facpub)

Follow this and additional works at: [https://uknowledge.uky.edu/sbcoa_facpub](https://uknowledge.uky.edu/sbcoa_facpub)

Part of the [Family, Life Course, and Society Commons](https://uknowledge.uky.edu/sbcoa_facpub), and the [Geriatrics Commons](https://uknowledge.uky.edu/sbcoa_facpub)

**Repository Citation**
[https://uknowledge.uky.edu/sbcoa_facpub/46](https://uknowledge.uky.edu/sbcoa_facpub/46)

This Editorial is brought to you for free and open access by the Aging at UKnowledge. It has been accepted for inclusion in Sanders-Brown Center on Aging Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
The neuropathology of dementia may not be in the consciousness of clinicians while evaluating patients with dementia. However, all clinicians should be aware of the importance of neuropathology to dementia diagnosis. For decades, β-amyloid deposited in senile plaques and tau in neurofibrillary tangles has dominated the dementia world, α-synuclein Lewy bodies being their sidekick. We now have a new member of the inner circle.

In 2006, investigators from the University of Pennsylvania reported that the transactive response DNA binding protein 43 (TDP-43) was aberrantly deposited in the brains of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration (FTLD). Little did they know how ubiquitous pathologic TDP-43 really was. A year later, investigators from the Mayo Clinic showed that pathologic TDP-43 was also present in the brains of patients with the most common cause of dementia, Alzheimer disease (AD). TDP-43 is a nucleotide binding protein that is present in the cell nuclei of normal brain cells (figure) and helps to regulate RNA processing. When TDP-43 is hyperphosphorylated, it accumulates in the cytoplasm of the cells (figure), a process that is cytotoxic via gain- or loss-of-toxic function mechanisms. In AD, pathologic TDP-43 follows a stereotypical pattern of deposition that has been captured by the TDP-43 in AD (TAD) staging scheme: TDP-43 first deposits in the amygdala (stage I), followed by hippocampus, limbic, temporal, and finally frontostriatum (stage V). The presence and burden of TDP-43 deposition modifies clinical and radiologic phenotype and are strongly associated with memory loss and hippocampal atrophy, the 2 cardinal clinical features of AD. This observed stereotypical pattern of deposition, and the clinical–pathologic correlation, suggest that TDP-43 should join the inner circle of neurodegenerative misfolded proteins that now include β-amyloid, tau, and α-synuclein.

The sheer prevalence and influence of TDP-43 pathology are remarkable. This pathology occurs in almost 60% of brains of patients with AD, and also in 90% of cases of dementia associated with progressive neuronal loss and gliosis of the CA1 and subiculum regions of the hippocampus, a phenomenon known as hippocampal sclerosis. Genetic risk factors for hippocampal sclerosis in aged persons, recently characterized, reveal new insights into disease mechanisms. In contrast to AD, APOE alleles are not implicated in hippocampal sclerosis, whereas alleles in the genes GRN, TMEM106B, ABCC9, and KCNMB2 are linked to this age-related hippocampal TDP-43 pathology.

In this issue of Neurology® , Yu et al. from Rush University Medical Center provide an important contribution related to the pathogenesis of TDP-43 pathology in older persons. This study focuses on the transmembrane protein 106B gene (TMEM106B), a genetic risk factor for the accumulation of abnormal TDP-43 in FTLD, AD, and hippocampal sclerosis. In their study of 544 autopsied participants from 2 community-based studies of aging, the authors confirmed that common variants in TMEM106B were indeed a distinct risk factor for TDP-43 pathology in older patients. This observation again underscores the importance of pathobiology-based endophenotypes in studies related to genetic risk factors. Capitalizing on their outstanding clinically and pathologically evaluated research cohort, the study delves into the complex interrelationships among comorbid pathologies of older persons that include AD, α-synucleinopathy, hippocampal sclerosis, and TDP-43 pathology. The authors also aimed to better understand the biological mechanisms underlying the relationship between TMEM106B variants and the deposition of TDP-43. This study breaks new ground by exploring novel pathways involving DNA methylation and miRNA and mRNA expression. Their data and analyses provide key support for the hypothesis that TMEM106B variants are pathogenetically important and exert their influence upstream of expression of GRN, a gene that is also strongly implicated in FTLD pathogenesis. A more theoretical mechanism is hypothesized related to increased inflammation of the brain although the exact mechanism remains elusive. The big picture is that heritable factors have strong influence on late-life neurologic conditions. While daunting to consider the importance of genes in dementia risk, this story could have a silver lining, whereby therapeutic intervention could occur at the preclinical stage in individuals genetically determined to be at risk of having TDP-43-associated dementias.
There is no turning back from this developing story of dementia due to multiple proteins and mixed pathologies. It is the rule, and not the exception, for older persons’ brains to harbor multiple comorbid pathologies, and TDP-43 is a prime player. This important new study highlights the importance of better delineation of the currently indistinct boundary areas among AD, hippocampal sclerosis, and TDP-43 pathology in advanced old age. Future studies are also needed to determine whether there are other risk factors for the deposition of TDP-43, to better understand the mechanism of TDP-43 transformation to pathologic TDP-43, for the development of biomarkers that can detect TDP-43 antemortem, and the ultimate goal of therapeutic interventions that target pathologic TDP-43.

STUDY FUNDING
No targeted funding reported.

DISCLOSURE
K. Josephs receives research support from the NIH (NIA and NIDCD) and the Alzheimer’s Association. P. Nelson receives research support from the NIH (NIA and NINDS) and the Alzheimer’s Drug Discovery Foundation. Go to Neurology.org for full disclosures.

REFERENCES